Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Do Wall Street Analysts Like Incyte Corporation Stock?

Headquartered in Wilmington, Delaware, Incyte Corporation (INCY) discovers, develops, and commercializes innovative therapies that confront some of medicine’s toughest challenges. Commanding a market cap of roughly $19.6 billion, the company targets blood cancers, solid tumors, immune-mediated disorders, and dermatological diseases.

Over the past 52 weeks, INCY stock has surged 49%, comfortably eclipsing the S&P 500 Index ($SPX) 14.4% gain during the same period. Year-to-date (YTD), INCY stock remains marginally positive, while the broader index has gained 1.4%. 

Fundamentals

See More
  • Market Capitalization, $K 19,404,562
  • Shares Outstanding, K 196,323
  • Annual Sales, $ 4,241 M
  • Annual Income, $ 32,610 K
  • EBIT $ 1,481 M
  • EBITDA $ 1,570 M
  • 60-Month Beta 0.82
  • Price/Sales 3.82
  • Price/Cash Flow 196.95
  • Price/Book 4.60

Options Overview Details

View History
  • Implied Volatility 36.43% (+4.73%)
  • Historical Volatility 43.42%
  • IV Percentile 43%
  • IV Rank 28.93%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 8) 4.31 (4.36%)
  • Put/Call Vol Ratio 1.52
  • Today's Volume 1,130
  • Volume Avg (30-Day) 826
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 16,418
  • Open Int (30-Day) 16,288
  • Expected Range 94.53 to 103.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.34
  • Number of Estimates 3
  • High Estimate 1.49
  • Low Estimate 1.23
  • Prior Year 0.89
  • Growth Rate Est. (year over year) +50.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.25 +1.50%
on 02/11/26
109.48 -9.84%
on 02/09/26
-7.63 (-7.17%)
since 01/12/26
3-Month
93.54 +5.52%
on 12/12/25
112.29 -12.10%
on 01/07/26
-9.56 (-8.83%)
since 11/12/25
52-Week
53.56 +84.29%
on 04/09/25
112.29 -12.10%
on 01/07/26
+29.65 (+42.95%)
since 02/12/25

Most Recent Stories

More News
Do Wall Street Analysts Like Incyte Corporation Stock?

Wall Street is keeping a confident yet pragmatic stance on Incyte Corporation, supported by steady growth and a promising pipeline.

$SPX : 6,967.65 (+0.38%)
INCY : 99.57 (+0.74%)
XBI : 123.90 (-0.60%)
INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow

INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow

INCY : 99.57 (+0.74%)
Broader Market Falls Ahead of Wednesday’s US Jobs Report

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.33%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.56%. March E-mini...

AVGO : 339.25 (-1.02%)
DHI : 167.99 (+2.53%)
ICHR : 45.94 (-3.47%)
BLDR : 127.79 (+0.67%)
DDOG : 129.41 (+1.63%)
$IUXX : 25,275.88 (+0.30%)
AMKR : 53.20 (-5.29%)
ASML : 1,431.00 (-0.32%)
RJF : 158.47 (-0.08%)
ZNH26 : 112-135 (+0.13%)
KBH : 65.42 (+2.35%)
SHOP : 110.70 (-6.75%)
Why Incyte (INCY) Stock Is Nosediving

Why Incyte (INCY) Stock Is Nosediving

INCY : 99.57 (+0.74%)
Stocks are Mixed After Weak Retail Sales Data Released

The S&P 500 Index ($SPX ) (SPY ) today is down -.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.25%. Stock indexes are mixed today....

ICHR : 45.94 (-3.47%)
DDOG : 129.41 (+1.63%)
$IUXX : 25,275.88 (+0.30%)
AMKR : 53.20 (-5.29%)
FT : 8.23 (unch)
ZNH26 : 112-135 (+0.13%)
SHOP : 110.70 (-6.75%)
STX : 451.00 (+10.74%)
WDC : 295.90 (+8.10%)
LRCX : 234.97 (-0.06%)
SPGI : 391.47 (+0.18%)
$DOWI : 50,350.03 (+0.46%)
Incyte (NASDAQ:INCY) Surprises With Q4 CY2025 Sales

Incyte (NASDAQ:INCY) Surprises With Q4 CY2025 Sales

INCY : 99.57 (+0.74%)
Incyte: Q4 Earnings Snapshot

Incyte: Q4 Earnings Snapshot

INCY : 99.57 (+0.74%)
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results

Total revenue of $1.51 billion (+28% Y/Y) in the fourth quarter 2025 and $5.14 billion (+21% Y/Y) for the full year 2025 Total net product revenue of $1.22 billion (+20%...

INCY : 99.57 (+0.74%)
Incyte (INCY) Q4 Earnings: What To Expect

Incyte (INCY) Q4 Earnings: What To Expect

INCY : 99.57 (+0.74%)
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Pending the European Commission decision, Zynyz ® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy...

INCY : 99.57 (+0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 102.54
2nd Resistance Point 101.17
1st Resistance Point 100.00
Last Price 99.57
1st Support Level 97.46
2nd Support Level 96.09
3rd Support Level 94.92

See More

52-Week High 112.29
Last Price 99.57
Fibonacci 61.8% 89.86
Fibonacci 50% 82.93
Fibonacci 38.2% 75.99
52-Week Low 53.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar